Management of metastases in regional lymph nodes in melanoma patients in 2019
Open Access
- 31 October 2019
- journal article
- Published by VM Media Group sp. z o.o in Nowotwory. Journal of Oncology
- Vol. 69 (3-4) , 108-110
Abstract
For several years, the standard of management in case of melanoma metastases in regional lymph nodes was to remove an adequate node group. In 2016 and 2017, the results of two large, well-designed clinical trials with randomization and a control group were published, which changed the current management. The authors of DeCOG-STL study came to the conclusion that withdrawal from completion lymph node dissection in the case of a small melanoma metastasis in a sentinel lymph node (metastasis diameter ≤1 mm) is not associated with a worsening of the 3-years’ survival chance (both in terms of overall survival and survival time to the occurrence of distant metastases). The results of MSTL-II study were similar. Based on the results of both studies presented above, in 2018 the American Society of Clinical Oncology (ASCO) and the Society of Surgical Oncology (SSO) presented joint recommendations concerning, among others, current indications for completion lymph node dissection in SNB positive melanoma patients. For several years, the standard of management in case of melanoma metastases in regional lymph nodes was to remove an adequate node group. In 2016 and 2017, the results of two large, well-designed clinical trials with randomization and a control group were published, which changed the current management. The authors of DeCOG-STL study came to the conclusion that withdrawal from completion lymph node dissection in the case of a small melanoma metastasis in a sentinel lymph node (metastasis diameter ≤1 mm) is not associated with a worsening of the 3-years’ survival chance (both in terms of overall survival and survival time to the occurrence of distant metastases). The results of MSTL-II study were similar. Based on the results of both studies presented above, in 2018 the American Society of Clinical Oncology (ASCO) and the Society of Surgical Oncology (SSO) presented joint recommendations concerning, among others, current indications for completion lymph node dissection in SNB positive melanoma patients.Keywords
This publication has 7 references indexed in Scilit:
- Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2018
- Improvement and persistent disparities in completion lymph node dissection: Lessons from the National Cancer DatabaseJournal of Surgical Oncology, 2017
- Completion Dissection or Observation for Sentinel-Node Metastasis in MelanomaNew England Journal of Medicine, 2017
- Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trialThe Lancet Oncology, 2016
- SEOM guidelines for the management of Malignant Melanoma 2015Clinical and Translational Oncology, 2015
- The Survival Benefit to Patients with Positive Sentinel Node Melanoma After Completion Lymph Node Dissection May Be Limited to the Subgroup with a Primary Lesion Breslow Thickness Greater Than 1.0 and Less Than or Equal to 4 mm (pT2–pT3)Annals of Surgical Oncology, 2008
- Compliance with Melanoma Treatment Guidelines in a Community Teaching Hospital: Time Trends and Other VariablesAnnals of Surgical Oncology, 2008